Cyclacel Pharmaceuticals, Inc. (CYCC)
| Market Cap | 13.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.72M |
| Shares Out | 9.99M |
| EPS (ttm) | -2.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,772 |
| Open | 1.44 |
| Previous Close | 1.40 |
| Day's Range | 1.36 - 1.44 |
| 52-Week Range | 1.29 - 7.84 |
| Beta | 1.39 |
| Analysts | Buy |
| Price Target | 20.40 (+1,378.3%) |
| Earnings Date | May 11, 2022 |
About CYCC
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced le...
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for CYCC stock is "Buy." The 12-month stock price forecast is 20.4, which is an increase of 1,378.26% from the latest price.
News
Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results
BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medi...
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors a...
- CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Types in Streamlined, Registration-Directed Study - - CYC140, a Potent and Sele...
Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax ...
-New Preclinical Data Highlight Fadraciclib's Apoptosis Enabling Mechanism in Leukemia-
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 –
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results
BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...
Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference
BERKELEY HEIGHTS, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...
Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022
– Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib –
Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference
BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelo...
Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluate...
Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update
BERKELEY HEIGHTS, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...
Cyclacel Pharmaceuticals Presenting at Three Conferences in September
BERKELEY HEIGHTS, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...
Cyclacel Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
- Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib - - Additional Phase 1/2 Trials for Fadraciclib and CYC140 Expected to Follow - - Cash Runway to Early 2023 - - Conference Call S...
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tum...
-Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated Across Multiple Solid Tumor and Lymphoma Types in Streamlined Registration-Directed Study- -Next-Generation CDK2/9 Inhibitor Fadraciclib to ...
Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann's Virtual 2021 Healthcare Conference
BERKELEY HEIGHTS, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...
Cyclacel Pharmaceuticals Reports First Quarter 2021 Financial Results
- Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors - - Recent Publication Reported that Overactive KRAS Mutants are Impeded by CDK9 Inhibition - - Following Rece...
Cyclacel Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Business Update
BERKELEY HEIGHTS, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medi...
Cyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and Full Exercise of Over-Al...
BERKELEY HEIGHTS, N.J., March 16, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...
Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference
BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...
Cyclacel Pharmaceuticals Presses Capital Raise Button
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) priced an underwritten public offering of 1.81 million common shares at $7 per share, a discount of 11% on the last close price of $7.87 on Thursday. It will ...
Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public Offering of Common Stock
BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...
Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock
BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...
Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & Investor Digital Conference
BERKELEY HEIGHTS, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...
Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021
– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer – – $7 Million Strategic Investment by Fun...
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021
BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative med...
Cyclacel Pharmaceuticals to Release Third Quarter Financial Results
BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medic...